Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Receivables (2016 - 2025)

Mimedx's Receivables history spans 15 years, with the latest figure at $84.4 million for Q4 2025.

  • For Q4 2025, Receivables rose 51.2% year-over-year to $84.4 million; the TTM value through Dec 2025 reached $84.4 million, up 51.2%, while the annual FY2025 figure was $84.4 million, 51.2% up from the prior year.
  • Receivables for Q4 2025 was $84.4 million at Mimedx, up from $83.6 million in the prior quarter.
  • Across five years, Receivables topped out at $84.4 million in Q4 2025 and bottomed at $35.5 million in Q1 2021.
  • The 5-year median for Receivables is $50.1 million (2023), against an average of $52.2 million.
  • The largest annual shift saw Receivables rose 0.05% in 2022 before it skyrocketed 54.73% in 2025.
  • A 5-year view of Receivables shows it stood at $40.4 million in 2021, then grew by 6.77% to $43.1 million in 2022, then rose by 25.04% to $53.9 million in 2023, then rose by 3.63% to $55.8 million in 2024, then surged by 51.2% to $84.4 million in 2025.
  • Per Business Quant, the three most recent readings for MDXG's Receivables are $84.4 million (Q4 2025), $83.6 million (Q3 2025), and $73.2 million (Q2 2025).